-
公开(公告)号：EP2632954B1
公开(公告)日：2015-11-25
申请号：EP11787633.4
申请日：2011-10-27
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2809 , A61K39/39558 , A61K2039/505 , A61K2039/545 , C07K16/2803 , C07K2317/31 , C07K2317/76
-
公开(公告)号：EP2637670A1
公开(公告)日：2013-09-18
申请号：EP11788077.3
申请日：2011-10-27
IPC分类号： A61K31/573 , A61K39/395 , C07K16/28
CPC分类号： A61K31/573 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2300/00 , C07K16/2803 , C07K16/2809 , C07K2317/31
摘要： The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
-
公开(公告)号：EP2632954A1
公开(公告)日：2013-09-04
申请号：EP11787633.4
申请日：2011-10-27
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2809 , A61K39/39558 , A61K2039/505 , A61K2039/545 , C07K16/2803 , C07K2317/31 , C07K2317/76
摘要： The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19 x CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, "BiTE") is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
-
公开(公告)号：EP2493503A1
公开(公告)日：2012-09-05
申请号：EP10771102.0
申请日：2010-10-27
IPC分类号： A61K39/395 , C07K16/46 , G01N33/574
CPC分类号： C07K16/2809 , A61K2039/505 , A61K2039/545 , A61K2039/55 , C07K16/2803 , C07K2317/31 , G01N33/505 , G01N33/5052 , G01N33/5094 , G01N2800/52
摘要： The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19xCD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19x CD3 bispecific antibody to a human patient having a B :T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use of a CD19x CD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well.
-
5.发明公开
公开(公告)号：EP3760210A1
公开(公告)日：2021-01-06
申请号：EP20182831.6
申请日：2014-02-07
发明人： KLINGER, Matthias , HOFFMANN, Patrick , NAEGELE, Virginie , DOPFER, Elaine-Pashupati , NAGORSEN, Dirk , SCHEELE, Juergen , ZUGMAIER, Gerhard , KUFER, Peter
IPC分类号： A61K31/737
摘要： The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
-
公开(公告)号：EP3228315B1
公开(公告)日：2020-11-25
申请号：EP17159560.6
申请日：2011-10-27
IPC分类号： A61K31/573 , A61K39/395 , C07K16/28
-
公开(公告)号：EP3412687A1
公开(公告)日：2018-12-12
申请号：EP18164175.4
申请日：2011-10-27
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , A61P35/00
摘要： The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19 x CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, "BiTE") is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
-
8.发明公开
公开(公告)号：EP3228315A1
公开(公告)日：2017-10-11
申请号：EP17159560.6
申请日：2011-10-27
IPC分类号： A61K31/573 , A61K39/395 , C07K16/28
CPC分类号： A61K31/573 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2300/00 , C07K16/2803 , C07K16/2809 , C07K2317/31
摘要： The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
摘要翻译： 本发明涉及用于改善，治疗或预防由CD3结合结构域引起的神经/精神不良事件的糖皮质激素（GC）。 还公开了包含GC，CD3结合结构域和指示GC用于治疗改善和/或预防由所述CD3结合结构域引起的神经不良事件的使用说明的试剂盒。
-
9.发明授权PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS 有权VERMEIDUNGUNERWÜNSCHTERWIRKUNGEN DURCH CD3-SPEZIFISCHEBINDUNGSDOMÄNEN
公开(公告)号：EP2637670B1
公开(公告)日：2017-03-08
申请号：EP11788077.3
申请日：2011-10-27
IPC分类号： A61K31/573 , A61K39/395
CPC分类号： A61K31/573 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2300/00 , C07K16/2803 , C07K16/2809 , C07K2317/31
摘要： The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
摘要翻译： 本发明涉及用于改善，治疗或预防由CD3结合结构域引起的神经/精神不良事件的糖皮质激素（GC）。 还公开了包含GC，CD3结合结构域的试剂盒和指示用于治疗改善和/或预防由所述CD3结合结构域引起的神经功能不良事件的GC的使用说明书。
-
公开(公告)号：EP3018145A1
公开(公告)日：2016-05-11
申请号：EP15195076.3
申请日：2011-10-27
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2809 , A61K39/39558 , A61K2039/505 , A61K2039/545 , C07K16/2803 , C07K2317/31 , C07K2317/76
摘要： The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19 x CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, "BiTE") is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
摘要翻译： 本发明提供治疗弥漫性大B细胞淋巴瘤（DLBCL）的方法和方法。 具体地，通过其CD3结合部分与T细胞接合并通过其CD19结合部分（即，双特异性T细胞募集体“BiTE”）同时结合特异性淋巴瘤细胞表面上的CD19的双特异性CD19×CD3抗体是 用于治疗由患者DLBCL引起的淋巴管组织肿瘤和/或结外淋巴瘤。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.019 秒)
